Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status Prescription; Discontinued
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 71610-108; 50090-1490; 60687-553; 43063-463; 71052-611; 50090-0370; 12785-0002; 50090-0410; 0527-1109; 53002-2920; 71335-0275; 68788-9405; 71610-395; 0555-0071; 46287-009; 63187-978; 12785-0003; 66639-914; 0781-3056; 0555-0066; 70518-0096; 70518-2576; 51079-083
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityGlutathione peroxidase 1P04041Not Available26004706
HepatotoxicityAlanine aminotransferase 1P24298Not Available4000989; 707874; 110184
HepatotoxicityN-alpha-acetyltransferase 20P61599Not AvailableNot Available
HepatotoxicityAlbuminP02770Not Available26004706
HepatotoxicityCatalaseP04762Not Available26004706
HepatotoxicityN-alpha-acetyltransferase 20P61599Not Available3691615; 9922980
HepatotoxicityOmega-amidase NIT2Q9JHW2Not Available26004706
Systemic lupus erythematosusN-alpha-acetyltransferase 20P61599Not AvailableNot Available
Systemic lupus erythematosusN-alpha-acetyltransferase 20P61599Not Available3691615; 9922980
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coma17.02.09.0010.101924%Not Available
Coma hepatic17.02.09.002; 09.01.03.0050.008309%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.0010.057332%
Death08.04.01.001--
Dehydration14.05.05.0010.031851%
Delirium19.13.02.0010.025481%
Depressed level of consciousness17.02.04.0020.019111%
Depression19.15.01.001--
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.019111%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.004985%
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.101924%
Drug eruption08.01.06.015; 23.03.05.001; 10.01.01.0050.044592%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dysarthria19.19.03.001; 17.02.08.0010.025481%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.0020.012741%Not Available
Encephalitis17.06.05.001; 11.01.03.0080.050962%
Encephalopathy17.13.02.0010.095554%
Eosinophil count increased13.01.06.0040.012741%Not Available
Eosinophilia01.02.04.0010.044592%
Erythema23.03.06.001--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 12 Pages